Skip to main content
Top
Published in: BMC Urology 1/2021

Open Access 01-12-2021 | Prostate Cancer | Research article

One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study

Authors: Lin Yang, Jung Ae Lee, Emily Heer, Claire Pernar, Graham A. Colditz, Ratna Pakpahan, Kellie R. Imm, Eric H. Kim, Robert L. Grubb III, Kathleen Y. Wolin, Adam S. Kibel, Siobhan Sutcliffe

Published in: BMC Urology | Issue 1/2021

Login to get access

Abstract

Background

To examine one-year trajectories of urinary and sexual outcomes, and correlates of these trajectories, among prostate cancer patients treated by radical prostatectomy (RP).

Methods

Study participants were recruited from 2011 to 2014 at two US institutions. Self-reported urinary and sexual outcomes were measured at baseline before surgery, and 5 weeks, 6 months and 12 months after surgery, using the modified Expanded Prostate Cancer Index Composite-50 (EPIC-50). Changes in EPIC-50 scores from baseline were categorized as improved (beyond baseline), maintained, or impaired (below baseline), using previously-reported minimum clinically important differences.

Results

Of the 426 eligible participants who completed the baseline survey, 395 provided data on at least one EPIC-50 sub-scale at 5 weeks and 12 months, and were analyzed. Although all mean EPIC-50 scores declined markedly 5 weeks after surgery and then recovered to near (incontinence-related outcomes) or below (sexual outcomes) baseline levels by 12 months post-surgery, some men experienced improvement beyond their baseline levels on each sub-scale (3.3–51% depending on the sub-scale). Having benign prostatic hyperplasia (BPH) at baseline (prostate size ≥ 40 g; an International Prostate Symptom Index Score ≥ 8; or using BPH medications) was associated with post-surgical improvements in voiding dysfunction-related bother at 5 weeks (OR = 3.9, 95% CI: 2.1–7.2) and 12 months (OR = 3.3, 95% CI: 2.0–5.7); and in sexual bother at 5 weeks (OR = 5.7, 95% CI:1.7–19.3) and 12 months (OR = 3.0, 95% CI: 1.2–7.1).

Conclusions

Our findings provide additional support for considering baseline BPH symptoms when selecting the best therapy for early-stage prostate cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59(6):379–90.CrossRef Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59(6):379–90.CrossRef
2.
go back to reference Barry MJ. Quality of life and prostate cancer treatment. J Urol. 1999;162(2):407.CrossRef Barry MJ. Quality of life and prostate cancer treatment. J Urol. 1999;162(2):407.CrossRef
3.
go back to reference Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.CrossRef Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.CrossRef
4.
go back to reference McNutt RA. Shared medical decision making: problems, process, progress. JAMA. 2004;292(20):2516–8.CrossRef McNutt RA. Shared medical decision making: problems, process, progress. JAMA. 2004;292(20):2516–8.CrossRef
5.
go back to reference Ferrer M, Suarez JF, Guedea F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):421–32.CrossRef Ferrer M, Suarez JF, Guedea F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):421–32.CrossRef
6.
go back to reference Tseng TY, Kuebler HR, Cancel QV, Sun L, Springhart WP, Murphy BC, Albala DM, Dahm P. Prospective health-related quality-of-life assessment in an initial cohort of patients undergoing robotic radical prostatectomy. Urology. 2006;68(5):1061–6.CrossRef Tseng TY, Kuebler HR, Cancel QV, Sun L, Springhart WP, Murphy BC, Albala DM, Dahm P. Prospective health-related quality-of-life assessment in an initial cohort of patients undergoing robotic radical prostatectomy. Urology. 2006;68(5):1061–6.CrossRef
7.
go back to reference Muramaki M, Miyake H, Behnsawy HM, Furukawa J, Harada K, Fujisawa M. Assessment of postoperative quality of life: comparative study between laparoscopic and minimum incision endoscopic radical prostatectomies. Int J Clin Oncol. 2014;19(6):1092–7.CrossRef Muramaki M, Miyake H, Behnsawy HM, Furukawa J, Harada K, Fujisawa M. Assessment of postoperative quality of life: comparative study between laparoscopic and minimum incision endoscopic radical prostatectomies. Int J Clin Oncol. 2014;19(6):1092–7.CrossRef
8.
go back to reference Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int. 2012;109(6):898–905.CrossRef Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int. 2012;109(6):898–905.CrossRef
9.
go back to reference Parker WR, Wang R, He C, Wood DP Jr. Five year expanded prostate cancer index composite-based quality of life outcomes after prostatectomy for localized prostate cancer. BJU Int. 2011;107(4):585–90.CrossRef Parker WR, Wang R, He C, Wood DP Jr. Five year expanded prostate cancer index composite-based quality of life outcomes after prostatectomy for localized prostate cancer. BJU Int. 2011;107(4):585–90.CrossRef
10.
go back to reference Miyake H, Miyazaki A, Furukawa J, Hinata N, Fujisawa M. Prospective assessment of time-dependent changes in quality of life of Japanese patients with prostate cancer following robot-assisted radical prostatectomy. J Robot Surg. 2016;10(3):201–7.CrossRef Miyake H, Miyazaki A, Furukawa J, Hinata N, Fujisawa M. Prospective assessment of time-dependent changes in quality of life of Japanese patients with prostate cancer following robot-assisted radical prostatectomy. J Robot Surg. 2016;10(3):201–7.CrossRef
11.
go back to reference Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010; 28(31):4687–4696. Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010; 28(31):4687–4696.
12.
go back to reference Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, et al. Prospective quality-of-life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy. Cancer. 2015;121(14):2465–73.CrossRef Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, et al. Prospective quality-of-life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy. Cancer. 2015;121(14):2465–73.CrossRef
13.
go back to reference Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS et al. Relief of urinary symptom burden after primary prostate cancer treatment. J Urol 2016. Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS et al. Relief of urinary symptom burden after primary prostate cancer treatment. J Urol 2016.
14.
go back to reference Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683–90.CrossRef Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683–90.CrossRef
15.
go back to reference Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRef Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRef
16.
go back to reference Yang L, Kibel AS, Colditz GA, Pakpahan R, Imm KR, Izadi S, Grubb RL 3rd, Wolin KY, Sutcliffe S. Caution with use of the expanded prostate cancer index composite-50 urinary bother scale: how voiding dysfunction modifies its performance. J Urol. 2017;198(6):1397–403.CrossRef Yang L, Kibel AS, Colditz GA, Pakpahan R, Imm KR, Izadi S, Grubb RL 3rd, Wolin KY, Sutcliffe S. Caution with use of the expanded prostate cancer index composite-50 urinary bother scale: how voiding dysfunction modifies its performance. J Urol. 2017;198(6):1397–403.CrossRef
17.
go back to reference Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85(1):101–5.CrossRef Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85(1):101–5.CrossRef
18.
go back to reference Yang L, Lee J, Kibel AS, Pernar C, Colditz GA, Pakpahan R, Imm KR, Izadi S, Grubb RL III, Wolin KY, et al. One-year urinary and sexual outcome trajectories in prostate cancer patients treated by radical prostatectomy: a prospective study. Curr Oncol. 2020;27(1):e71. Yang L, Lee J, Kibel AS, Pernar C, Colditz GA, Pakpahan R, Imm KR, Izadi S, Grubb RL III, Wolin KY, et al. One-year urinary and sexual outcome trajectories in prostate cancer patients treated by radical prostatectomy: a prospective study. Curr Oncol. 2020;27(1):e71.
19.
go back to reference Romero FR, Romero AW, Filho TB, Kulysz D, Oliveira FC, Filho RT. The prostate exam. Health Educ J. 2011;71(2):239–50.CrossRef Romero FR, Romero AW, Filho TB, Kulysz D, Oliveira FC, Filho RT. The prostate exam. Health Educ J. 2011;71(2):239–50.CrossRef
20.
go back to reference Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–64.CrossRef Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–64.CrossRef
21.
go back to reference Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68(4):600–8.CrossRef Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68(4):600–8.CrossRef
22.
go back to reference Levinson AW, Bagga HS, Pavlovich CP, Mettee LZ, Ward NT, Link RE, Su LM. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy. J Urol. 2008;179(5):1818–22.CrossRef Levinson AW, Bagga HS, Pavlovich CP, Mettee LZ, Ward NT, Link RE, Su LM. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy. J Urol. 2008;179(5):1818–22.CrossRef
23.
go back to reference Buttyan R, Chen MW, Levin RM. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. Eur Urol. 1997;32(Suppl 1):32–9.PubMed Buttyan R, Chen MW, Levin RM. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. Eur Urol. 1997;32(Suppl 1):32–9.PubMed
24.
go back to reference Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19(5):609–29.CrossRef Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19(5):609–29.CrossRef
25.
go back to reference Fusco F, Creta M, De Nunzio C, Iacovelli V, Mangiapia F, Li Marzi V, Finazzi Agro E. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018;18(1):15.CrossRef Fusco F, Creta M, De Nunzio C, Iacovelli V, Mangiapia F, Li Marzi V, Finazzi Agro E. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018;18(1):15.CrossRef
26.
go back to reference Badr H, Taylor CL. Sexual dysfunction and spousal communication in couples coping with prostate cancer. Psychooncology. 2009;18(7):735–46.CrossRef Badr H, Taylor CL. Sexual dysfunction and spousal communication in couples coping with prostate cancer. Psychooncology. 2009;18(7):735–46.CrossRef
27.
go back to reference Pazmany E, Bergeron S, Verhaeghe J, Van Oudenhove L, Enzlin P. Dyadic sexual communication in pre-menopausal women with self-reported dyspareunia and their partners: associations with sexual function, sexual distress and dyadic adjustment. J Sex Med. 2015;12(2):516–28.CrossRef Pazmany E, Bergeron S, Verhaeghe J, Van Oudenhove L, Enzlin P. Dyadic sexual communication in pre-menopausal women with self-reported dyspareunia and their partners: associations with sexual function, sexual distress and dyadic adjustment. J Sex Med. 2015;12(2):516–28.CrossRef
28.
go back to reference Zhao C, Kwan Park J. Phosphodiesterase type 5 inhibitor and erectile dysfunction in lower urinary tract symptoms. Lower Urinary Tract Symptoms. 2012;4(Suppl 1):75–80.CrossRef Zhao C, Kwan Park J. Phosphodiesterase type 5 inhibitor and erectile dysfunction in lower urinary tract symptoms. Lower Urinary Tract Symptoms. 2012;4(Suppl 1):75–80.CrossRef
29.
go back to reference Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Moncada I. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. Int J Clin Pract. 2011;65(9):1005–13.CrossRef Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Moncada I. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. Int J Clin Pract. 2011;65(9):1005–13.CrossRef
Metadata
Title
One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study
Authors
Lin Yang
Jung Ae Lee
Emily Heer
Claire Pernar
Graham A. Colditz
Ratna Pakpahan
Kellie R. Imm
Eric H. Kim
Robert L. Grubb III
Kathleen Y. Wolin
Adam S. Kibel
Siobhan Sutcliffe
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2021
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-021-00845-0

Other articles of this Issue 1/2021

BMC Urology 1/2021 Go to the issue